ET Management Question 1
Transcript
The correct answer is use formal thrombotic risk stratification alongside assessment of bleeding risk, symptoms, comorbidities, disease features, and longitudinal trends. So, risk assessment in essential thrombocythemia is, for the most part, determined by advanced age, a history of thrombosis, thromboses. They get thromboses. But we recognize increasingly that risk is also influenced by driver mutation, so JAK2 V617F is a higher-risk mutation for thrombosis than calreticulin mutations. Also, subclonal mutations can influence risk.
Additionally, the risk of cardiovascular events is modifiable by the usual risk factors: hypertension, diabetes, hypercholesterolemia, obesity, sedentary lifestyle, smoking. So, the risk is really broad. We recognize that thrombotic risk is also likely tied into other hematologic parameters like leukocytosis, which has been shown in multiple studies in ET as well as polycythemia vera.
We are aware that these risks can be addressed by aspirin first and foremost, but also cytoreductive therapy, as we've been discussing, whether it's hydroxyurea, anagrelide historically. But also, increasingly, interferon alfa-2a and the approval of interferon alfa-2b in ET based on the SURPASS study, which, as a primary endpoint, included hematologic control, so controlling the white count under 10,000, the platelet count under 400,000, as well as symptom burden reduction, the absence of spleen enlargement or progressive splenomegaly, and within that 3-month period, the absence of thrombohemorrhagic complications.
References
- Tefferi A, Gangat N, Loscocco GG, et al. Essential thrombocythemia: a review. JAMA. 2025;333(8):701. doi:10.1001/jama.2024.25349
- Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697-718. doi:10.1002/ajh.27216
- Godfrey AL, Green AC, Harrison CN. Essential thrombocythemia: challenges in clinical practice and future prospects. Blood. 2023;141(16):1943-1953. doi:10.1182/blood.2022017625
- Sever M, Newberry KJ, Verstovsek S. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma. 2014;55(12):2685-2690. doi:10.3109/10428194.2014.893310
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed October 15, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Mesa R, Gill H, Zhang L, et al. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS-ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025;12(11):e862-e875. doi:10.1016/S2352-3026(25)00264-9
- Awada H, Voso M, Guglielmelli P, Gurnari C. Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers. 2020;12(7):1746. doi:10.3390/cancers1207174
- Park YH, Lee S, Mun Y, Park DJ. Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia. Cancer Med. 2023;12(7):8073-8082. doi:10.1002/cam4.5602
- Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453-471. doi:10.1111/j.1365-2141.2012.09179.x
- Tremblay D. Cytoreduction for ET and PV: who, what, when, and how? Hematol Am Soc Hematol. 2023;2023(1):660-666. doi:10.1182/hematology.2023000451
- Abu-Zeinah G, Hobbs GS, Rampal RK, et al. Molecular response, event-free survival, and treatment-free remission in myeloproliferative neoplasms: update and review with insights from MPN Asia 2026. Curr Hematol Malig Rep. 2026;21(1):21. doi:10.1007/s11899-026-00790-5
This presentation is funded by PharmaEssentia.
©2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.


